Navigation Links
Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
Date:12/4/2007

Two International Phase 3 Trials Evaluated Infrequent Dosing of Ustekinumab

in Nearly 2,000 Patients

HORSHAM, Pa. and BEERSE, Belgium, Dec. 4 /PRNewswire/ -- Centocor, Inc. and Janssen-Cilag International NV announced today that regulatory applications have been submitted requesting the approval of ustekinumab (CNTO 1275) in the United States and Europe for the treatment of adult patients with chronic moderate to severe plaque psoriasis. Centocor has submitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) and Janssen-Cilag International NV has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA). Ustekinumab is a new, human monoclonal antibody with a novel mechanism of action that targets the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), naturally occurring proteins that are important in regulating immune responses and that are thought to be associated with some immune-mediated inflammatory disorders, including psoriasis.

It is estimated that 125 million people worldwide have psoriasis, including two percent of both the U.S. and European populations, or some 7.5 million Americans and 10 million Europeans. Nearly one-quarter of people with psoriasis have cases that are considered moderate to severe.(1)

The submissions are based on a comprehensive development program including data from two large Phase 3 multicenter, randomized, double-blind, placebo- controlled trials involving nearly 2,000 patients that evaluated the safety and efficacy of ustekinumab in the treatment of moderate to severe plaque-type psoriasis. The primary endpoint of each pivotal study was the proportion of patients who achieved at least a 75 percent reduction in psoriasis as measured by the Psoriasis Area and Severity Index (PASI 75).

"We are very encouraged by the promising results that we have seen through the ustekinumab clinical developmen
'/>"/>

SOURCE Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CLIA Waiver Submitted for Rapid HIV Test Employs StatSures Barrel Technology
2. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
3. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
4. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
5. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
6. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
7. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
10. CryoCor Receives FDA Approval for Right Atrial Flutter
11. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Pomerantz LLP has ... or the "Company") (NASDAQ: EDAP ) and ... United States District Court, Southern District of ... on behalf of a class consisting of all persons ... 2013 and July 30, 2014, inclusive (the "Class Period"). This ...
(Date:8/29/2014)... Calif. , Aug. 29, 2014 Thoratec ... in device-based mechanical circulatory support therapies to save, support ... participating in the 2014 Morgan Stanley Global Healthcare Conference ... Burbach , President and Chief Executive Officer, will provide ... Eastern Daylight Time (9:55 a.m., Pacific Daylight Time).   ...
(Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3US CNS Disorders Drug Pipeline Insight 2014 2
... The annual meeting of the Chinese food industry is ... June, heavily focusing on the growing health market in China, and ... and discuss business developments in the country and beyond. ... and China continues to enjoy a global reputation for being a ...
... Amgen (Nasdaq: AMGN ) today announced the ... compared XGEVA ™ (denosumab) to Zometa ® (zoledronic ... 1,901 men with prostate cancer and bone metastases. The study, ... secondary endpoints and demonstrated XGEVA,s superiority compared to Zometa in ...
Cached Medicine Technology:Health on the Agenda at Food ingredients Asia-China Trade Show 2Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 2Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 3Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 4Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 5Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 6Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 7Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 8Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 9
(Date:8/31/2014)... The severity of menopausal symptoms will ... menopause is expert in helping patients find the ... uncomfortable symptoms with the latest treatment options, including hormone ... variety of alternative treatments and products that can relieve ... may fall outside of what can be called conventional ...
(Date:8/30/2014)... August 2014: A new method to predict the ... was presented at ESC Congress today by Dr Benjamin ... needs 350 AEDs located in public places for optimal ... Dr Dahan said: "Out of hospital cardiac arrest is ... ranging between 50 and 100 per 100 000 in ...
(Date:8/30/2014)... Colorado (PRWEB) August 31, 2014 According to ... proven step by step holistic system for skin health. It ... has already been tried by more than 138,000 patients from ... by Mike Walden, who says that this method will not ... permanent clear skin. , What makes this program unique ...
(Date:8/30/2014)... Zensah®, the leader in compression technology and comfort, ... a best-seller within golf and tennis. Golfers and tennis players ... most by using the compression elbow sleeve to help treat ... condition that causes pain on the inner side of your ... the bony bump on the inside of your elbow. The ...
(Date:8/30/2014)... The Truth about Six Pack Abs is ... to users some shocking foods that can burn belly fat, ... looks, as well as some motivation secrets for successful fitness. ... is one unique trick that can help users reduce junk-food ... many people might think, cardio exercise routines are not the ...
Breaking Medicine News(10 mins):Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 2Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 3Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 4Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 5Health News:New method predicts optimal number and location of AEDs 2Health News:Acne No More Review Reveals Unusual Tip to Eliminate Acne Permanently 2Health News:Relieve Golfers and Tennis Elbow Pain with the Zensah® Compression Elbow Sleeve 2Health News:Truth about Six Pack Abs Review Reveals Unique Method to Eliminate Stubborn Stomach Fat 2
... is sought by the U.S. Food and Drug Administration ... its President Judd J. Brown. // This will ... its products. The company's ready-to-eat fish is reported to ... has been initiated. ,The inspections conducted ...
... has been discovered in the peat swamps of Indonesia. This ... and an exposed brain. A mature female fish measures only ... researchers belonging to countries like the UK, Indonesia, Germany, Switzerland ... a report on this. This is also the world's tiniest ...
... Max-Planck Institute for Dynamics and Self-Organization in Gottingen conducted a ... the disease by tracking the spread of humans with the ... than $450000 worth of $1 bills through US using an ... human dispersal which would help the scientist fight against easily ...
... An Indonesian market vendor who came into close contact with ... the H5N1 strain of the bird flu virus.// Health authorities ... carried the virus. Blood and swab samples have been sent ... if that report is positive then the death toll in ...
... aloe vera, T-shirts with vitamin C and underwear that ... industry takes its cue from the food industry.// This ... addition to keeping the body warm. ... matter. Experts also fear the garments could lead to ...
... In an article published in the British Medical Journal, Nadine ... say that the ventilation systems supposed to prevent tobacco smoke ... ineffective. // ,The report also says ... systems do not work, but still proceeded to install them ...
Cached Medicine News:Health News:Tracking the spread of disease with the help of money 2Health News:Scented Garments Hit The Market 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: